PILOT CLINICAL STUDY OF GCSF IN COMBINATION WITH DESIPRAMINE FOR AUTOLOGOUS STEM CELL MOBILIZATION IN MULTIPLE MYELOMA
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 04 Feb 2019
Price : $35 *
At a glance
- Drugs Desipramine (Primary) ; Filgrastim (Primary)
- Indications Multiple myeloma; Stem cell mobilisation
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 11 Jan 2016 Planned primary completion date changed from 1 Jan 2016 to 1 March 2015 as reported by ClinicalTrials.gov record.
- 05 Mar 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.